Skip to Main Content
Skip Nav Destination

A key quality attribute of any ADC is the mode of attachment of the linker-drug to the monoclonal antibody. Early generation technologies were based exclusively on one of two approaches, i.e. covalent bond formation with – abundantly available – lysine or cysteine sidechains. However, the need to develop ADCs with increased therapeutic index, and the insight that homogeneity, proper site selection, and stability all play a key role in this matter, has served as an inspiration for the development of a contemporary conjugation toolbox filled with alternative conjugation approaches. This chapter discusses in depth the state of the art in antibody conjugation, providing a comprehensive overview of technologies currently employed in clinical and late-stage preclinical ADC programs. The pros and cons of each technology are also discussed. Besides, a range of promising emerging technologies is highlighted, judged on their potential for application in next-generation ADCs.

You do not currently have access to this chapter, but see below options to check access via your institution or sign in to purchase.
Don't already have an account? Register
Close Modal

or Create an Account

Close Modal
Close Modal